Approximately 15–20% of patients with breast cancer have tumors that overexpress human epidermal growth factor receptor 2 (HER2), which are associated with an aggressive clinical phenotype and poor prognosis [1, 2]. Here, ERBB2 is linked to breast carcinoma.